Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Cancer. 2013 Aug 15; 119(16):3043-51.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.